Choroid plexus volumetrics and brain inflammation in multiple sclerosis von Manouchehri, Navid, Stüve, Olaf

Volltext

Extended-interval dosing of natalizumab in NOVA von Stüve, Olaf, Tugemann, Bastian

Volltext

Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology von Shirani, Afsaneh, Stüve, Olaf

Volltext

Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis von Berger, Thomas, Stüve, Olaf

Volltext

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets von Forsthuber, Thomas G., Cimbora, Daniel M., Ratchford, John Nolan, Katz, Eliezer, Stüve, Olaf

Volltext

The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis von Milo, Ron, Korczyn, Amos D, Manouchehri, Navid, Stüve, Olaf

Volltext

Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment von Manouchehri, Navid, Stüve, Olaf

Volltext

Trials and therapies in secondary progressive MS, simplified von Manouchehri, Navid, Stüve, Olaf

Volltext

Evolution of clinical trials in multiple sclerosis von Zhang, Yinan, Salter, Amber, Wallström, Erik, Cutter, Gary, Stüve, Olaf

Volltext

Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control? von Negron, Austin, Stuve, Olaf, Forsthuber, Thomas G.

Volltext

The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors von Sellner, Johann, Kraus, Jörg, Awad, Amer, Milo, Ron, Hemmer, Bernhard, Stüve, Olaf

Volltext

Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity von Manouchehri, Navid, Salinas, Victor H, Hussain, Rehana Z, Stüve, Olaf

Volltext

Simplification of combination antiretroviral therapy (cART) and the brain—a real-life experience von Arendt, Gabriele, Schlonies, Svenja, Orhan, Eser, Stüve, Olaf

Volltext

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study von Selmaj, Krzysztof, Prof, Li, David KB, Prof, Hartung, Hans-Peter, Prof, Hemmer, Bernhard, Prof, Kappos, Ludwig, Prof, Freedman, Mark S, Prof, Stüve, Olaf, MD, Rieckmann, Peter, Prof, Montalban, Xavier, Prof, Ziemssen, Tjalf, MD, Auberson, Lixin Zhang, MD, Pohlmann, Harald, MSc, Mercier, Francois, PhD, Dahlke, Frank, MD, Wallström, Erik, MD

Volltext

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome von Okuda, Darin T., Kantarci, Orhun, Lebrun‐Frénay, Christine, Sormani, Maria Pia, Azevedo, Christina J., Bovis, Francesca, Hua, Le H., Amezcua, Lilyana, Mowry, Ellen M., Hotermans, Christophe, Mendoza, Jason, Walsh, John S., Hehn, Christian, Vargas, Wendy S., Donlon, Stacy, Naismith, Robert T., Okai, Annette, Pardo, Gabriel, Repovic, Pavle, Stüve, Olaf, Siva, Aksel, Pelletier, Daniel

Volltext

The major histocompatibility complex and antibody‐mediated limbic encephalitis von Stüve, Olaf, Vernino, Steven

Volltext

Clinical trials in multiple sclerosis: milestones von Zhang, Yinan, Salter, Amber, Cutter, Gary, Stüve, Olaf

Volltext

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study von Kappos, Ludwig, Li, David K. B, Stüve, Olaf, Hartung, Hans-Peter, Freedman, Mark S, Hemmer, Bernhard, Rieckmann, Peter, Montalban, Xavier, Ziemssen, Tjalf, Hunter, Brian, Arnould, Sophie, Wallström, Erik, Selmaj, Krzysztof

Volltext

Alemtuzumab: The advantages and challenges of a novel therapy in MS von Menge, Til, Stüve, Olaf, Kieseier, Bernd C, Hartung, Hans-Peter

Volltext

Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis von Stüve, Olaf, Racke, Michael K

Volltext